Kanaph Therapeutics Inc. (KOSDAQ:0082N0)

South Korea · Delayed Price · Currency is KRW

39,500

+1,850 (4.91%)

At close: Apr 27, 2026

-42.00% (1Y)

Market Cap	497.53B
Revenue	n/a
Net Income	n/a
Shares Out	13.09M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,504
Average Volume	258,659
Open	38,200
Previous Close	37,650
Day's Range	38,150 - 40,600
52-Week Range	32,850 - 70,000
Beta	n/a
RSI	43.66
Earnings Date	n/a

About Kanaph Therapeutics

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker ther... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2019

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 0082N0

Full Company Profile

News

There is no news available yet.